Bicycle Therapeutics (BCYC) has disclosed a new risk, in the Share Price & Shareholder Rights category.
Bicycle Therapeutics operates under a notable concentration of ownership, which poses a significant business risk. The Baker Entities, owning approximately 19.9% of the company’s shares, along with Felix J. Baker’s position on the board, can heavily influence corporate decisions. This control, combined with other major shareholders, results in about 44% of voting power, potentially leading to actions that might not align with the interests of minority shareholders. Such dominance could deter potential takeovers or other corporate changes, possibly affecting the market value of Bicycle Therapeutics’ shares.
The average BCYC stock price target is $40.22, implying 77.10% upside potential.
To learn more about Bicycle Therapeutics’ risk factors, click here.
